...
首页> 外文期刊>Washington Drug Letter >FDA Forces LABA Drugmakers To Change Label, Add REMS
【24h】

FDA Forces LABA Drugmakers To Change Label, Add REMS

机译:FDA强迫LABA药品制造商更改标签,添加REMS

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The FDA has flexed its recently acquired enforcement muscles once again, forcing a label change for the long acting beta-2 agonist (LABA) class of drugs in an effort to reduce their use without another asthma controller medicine such as an inhaled corticosteroid.rnIn February, the agency issued a request for companies to change the labels themselves after the FDA's analyses of studies showed an increased risk of severe exacerbation of asthma symptoms leading to hospitalizations when LAB As are used alone.
机译:FDA再次展示了其最近获得的执行力,迫使长效β-2激动剂(LABA)类药物的标签更改,以减少在没有另一种哮喘控制药物(例如吸入皮质类固醇)的情况下减少使用。 ,FDA的研究分析表明,单独使用LAB As会严重加重哮喘症状,导致住院治疗的风险增加,FDA要求公司自行更改标签。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号